drugset / Trial / NCT06281236

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

NCT06281236

Phase 1 Terminated 1 enrolled Sparrow Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited.

Timeline

Start
2022-02-22
Primary completion
2025-03-25
Completion
2025-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisolone Other / unclassified
Subject clofutriben Small molecule